Related Experiment Video
Updated: May 7, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Primary pulmonary hypertension. A national prospective study.
Primary pulmonary hypertension diagnosis is often delayed, taking a mean of two years from symptom onset. Early detection strategies are crucial for better patient outcomes in this serious cardiopulmonary condition.
Area of Science:
- Cardiology
- Pulmonology
- Epidemiology
Background:
- Primary pulmonary hypertension (PPH) is a rare and severe condition.
- A national registry was established to gather data on PPH patients.
Purpose of the Study:
- To characterize the clinical presentation and diagnostic interval of patients with primary pulmonary hypertension.
- To identify factors influencing diagnosis and highlight the need for earlier detection.
Main Methods:
- Data collected from 32 centers on 187 PPH patients diagnosed using uniform criteria.
- Analysis of patient demographics, symptoms, medical history, and diagnostic test results.
Main Results:
- Mean age of diagnosis was 36 years, with a 1.7:1 female-to-male ratio.
- Common symptoms included dyspnea (60%), fatigue (19%), and syncope (13%).
- Pulmonary function showed restriction, reduced diffusing capacity, and hypoxemia; hemodynamic data revealed elevated pressures and reduced cardiac index.
Conclusions:
- A significant delay exists between symptom onset and diagnosis of PPH, averaging two years.
- The findings underscore the urgent need for improved diagnostic strategies to facilitate earlier identification of PPH.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

